Table I.
Clinical Characteristics of 157 Black Patients with Mycosis Fungoides / Sézary Syndrome
| Patient Characteristic | Value |
|---|---|
| Age at diagnosis, mean (range), y | 47.9 (12–88) |
| Female-male ratio (No.:No.) | 1.6 (97:60) |
| Diagnosis delay from onset of symptoms, mean (range), m | 4.0 (0.1–30) |
| Referral delay from diagnosis, mean (range), y | 2.2 (0–156.3) |
| Birth place, No. (%) | |
| US | 68 (43) |
| Non-US | 31 (20) |
| Unknown | 58 (37) |
| Ethnicity, No. (%) | |
| Non-Hispanic | 142 (90) |
| Hispanic | 8 (5) |
| Unknown | 7 (5) |
| Healthcare coverage, No. (%) | |
| Medicaid | 21 (13) |
| Medicare | 24 (15) |
| Private/HMO | 105 (67) |
| Unknown | 7 (5) |
| Median Household Income, No. (%) | |
| $1–37,999 | 33 (21) |
| $38,000–47,999 | 29 (18) |
| $48,000–63,999 | 26 (17) |
| $64,000 or more | 60 (38) |
| Unknown | 9 (6) |
| Poverty rate (per ZIP code), No. (%) | |
| ≤20% | 93 (59) |
| >20% | 55 (35) |
| Unknown | 9 (6) |
| Most severe type of skin lesions, No. (%) | |
| Patches | 84 (53) |
| Plaques | 48 (31) |
| Tumors and nodules | 15 (10) |
| Erythroderma | 9 (6) |
| Unknown | 1 (0) |
| Color of lesions, No. (%) | |
| Erythematous | 44 (28) |
| Hypopigmented | 71 (45) |
| Hyperpigmented | 83 (53) |
| Unknown | 5 (3) |
| Follicular involvement, No. (%) | 17 (11) |
| Ulceration, No. (%) | 2 (1) |
| Clinical Stage, No. (%) | |
| IA | 31 (20) |
| IB | 80 (51) |
| IIA | 11 (7) |
| IIB | 14 (9) |
| IIIA + IIIB | 4 (2) |
| IVA + IVB | 17 (11) |
| Immunophenotype per IHC on initial skin biopsy, No. (%) | |
| CD4+ | 64 (41) |
| CD8+ | 30 (19) |
| Unknown | 63 (40) |
| Large cell transformation, No. (%) | 23 (15) |
| Initial treatment, No. (%) | |
| Topical steroids alone | 21 (13) |
| Topical nitrogen mustard alone | 3 (2) |
| Phototherapy NBUVB / PUVA | 68* (43) / 10** (6) |
| Radiation Local / TSEB | 2 (1) / 11 (7) |
| Oral bexarotene | 11 (7) |
| Oral methotrexate | 2 (1) |
| Romidepsin | 6 (4) |
| Brentuximab | 2 (1) |
| Chemotherapy | 8 (5) |
| Observation | 1 (<1) |
| Lost to follow-up | 8 (5) |
| Unavailable | 4 (3) |
Abbreviations: US, United States; HMO, health maintenance organization; IHC, immunohistochemistry; NBUVB, Narrowband ultraviolet B; TSEB, total skin electron beam
+Median household income national quartile for patient residential ZIP code
++Individuals below poverty line in patient residential ZIP code
*
combined with oral bexarotene in 5 cases.
**
combined with interferon in one case and with interferon and oral bexarotene in one case.